Larimar Therapeutics
LRMR
104 hedge funds and large institutions have $483M invested in Larimar Therapeutics in 2024 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 33 increasing their positions, 23 reducing their positions, and 5 closing their positions.
720% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 5
415% more call options, than puts
Call options by funds: $9.71M | Put options by funds: $1.89M
168% more capital invested
Capital invested by funds: $180M → $483M (+$303M)
51% more funds holding
Funds holding: 69 → 104 (+35)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 23
9.72% more ownership
Funds ownership: 89.99% → 99.71% (+9.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$47.1M |
| 2 |
DM
Deerfield Management
New York
|
+$33.4M |
| 3 |
Goldman Sachs
New York
|
+$25.6M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$10.8M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$8.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$10.2M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.5M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.28M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$913K |
| 5 |
Morgan Stanley
New York
|
-$508K |
LRMR Hedge Fund Activity: Q1 2024 in Review
104 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q1 2024, worth a combined $483M — up 168% from $180M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new LRMR positions and 5 closed out — a net gain of 36 holders — while 33 added to existing stakes and 23 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $47.1M. The largest seller was Verition Fund Management, cutting an estimated $10.2M.
- 104 institutional investors held Larimar Therapeutics (LRMR) as of Q1 2024, up from 69 in Q4 2023.
- Funds reported $483M of Larimar Therapeutics stock for Q1 2024, up 168% quarter-over-quarter.
- 41 funds opened new Larimar Therapeutics positions in Q1 2024 and 5 closed out, a net change of +36 holders.
- The largest Larimar Therapeutics buyer in Q1 2024 was RA Capital Management, an estimated $47.1M added.
- The largest Larimar Therapeutics seller in Q1 2024 was Verition Fund Management, an estimated $10.2M sold.
Based on aggregated 13F filings for Q1 2024.